Phytomedicine 2010-04-01

ACE inhibition by astilbin isolated from Erythroxylum gonocladum (Mart.) O.E. Schulz.

M D Lucas-Filho, G C Silva, S F Cortes, T R Mares-Guia, V Perpétua Ferraz, C P Serra, F C Braga

Index: Phytomedicine 17(5) , 383-7, (2010)

Full Text: HTML

Abstract

Erythroxylum species have several traditional uses in different countries, including the treatment of hypertension. The ethanol extract from E. gonocladum aerial parts, a species endemic to the Brazilian cerrado, elicited a concentration-dependent inhibition of angiotensin converting enzyme (ACE) (pIC(50)=4.53+/-0.05). Extract fractionation led to the isolation of two compounds, whose structures were assigned by spectrometric data as astilbin and beta-sitosterol, along with a mixture of palmitic, stearic and linolenic acids. This is the first report on the occurrence of these compounds on E. gonocladum. Astilbin promoted significant ACE inhibition in vitro (pIC(50)=5.86+/-0.33) and its activity did not differ from captopril, when both compounds were assayed at 10 microM concentration.Copyright 2009 Elsevier GmbH. All rights reserved.


Related Compounds

Related Articles:

Isolation and characterization of two flavonoids, engeletin and astilbin, from the leaves of Engelhardia roxburghiana and their potential anti-inflammatory properties.

2011-05-11

[J. Agric. Food Chem. 59(9) , 4562-9, (2011)]

Chemical constituents comparison between Rhizoma Smilacis Glabrae and Rhizoma Smilacis Chinae by HPLC-DAD-MS/MS.

2013-01-01

[Nat. Prod. Res. 27(3) , 277-81, (2013)]

Induction of TGF-_ and IL-10 production in dendritic cells using astilbin to inhibit dextran sulfate sodium-induced colitis.

2014-04-01

[Biochem. Biophys. Res. Commun. 446(2) , 529-34, (2014)]

Effect of astilbin on experimental diabetic nephropathy in vivo and in vitro.

2009-11-01

[Planta Med. 75(14) , 1470-5, (2009)]

Development of HPLC fingerprint for species differentiation and quality assessment of Rhizoma Smilacis Glabrae.

2013-01-01

[J. Nat. Med. 67(1) , 207-11, (2013)]

More Articles...